INNOCARE(09969.HK)

Event Tracking

Dec24

Guoyuan International Publishes Report with Positive Outlook on Novarellas 2025-2027 Prospects

07:06

Dec23

Novel TYK2 Inhibitor ICP-488 by Novartis Approved for Phase II Clinical Trials

01:38

Dec18

Nocia Healthcare's Aubitini IIb Clinical Trial for Systemic Lupus Erythematosus Achieves Primary Endpoint

07:12

Dec15

Novocres Advances Orelabrutinib into Phase III Clinical Trials

03:08

Dec14

Nocile's Aubitini Reaches Primary Endpoint in Phase IIb Clinical Trial for Systemic Lupus Erythematosus, Approved for Phase III Registration Clinical Trial

08:17

Dec11

Novartis Joins Genentech in Securing Approval for Next-Generation TRK Inhibitor Zoratet 骖 bine

10:16

Schedules & Filings

Schedules

Filings

Nov13

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 419.66 M, Net Income -37.52 M, EPS -0.0205

Aug19

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 383.27 M, Net Income -52.6 M, EPS -0.0433

May13

Earning Release(CST)

FY2025 Q1 Earning Release (HKD) Revenue 408.32 M, Net Income 19.24 M, EPS 0.0107

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change